| Panel Discussion 1(JGES・JSGE) |
| Thu. October 31st 9:00 - 12:00 Room 2: Kobe International Exhibition Hall No.2 Building Hall (South) |
| Role of endoscopy for treatment of IBD in Europe | |||
| Marietta Iacucci | |||
| Gastroenterology at University College Cork | |||
|
|||
|
|||
| Endoscopic remission is the primary long-term therapeutic goal in Inflammatory Bowel Disease (IBD). The assessment of this therapeutic target typically relies on white light endoscopy (WLE) combined with random and targeted histological sampling, which guides patient therapeutic management. Nonetheless, distinguishing between endoscopic mild, patchy inflammation and quiescent disease can be challenging, and discrepancies have been observed between endoscopic and histologic disease activity, mainly when using WLE. Recent advances in endoscopic systems and evolving technologies are gradually transforming clinical practice. Dye-based chromoendoscopy and virtual chromoendoscopy are currently available in the endoscopist armamentarium, enhancing the assessment of mucosal architecture and vascular patterns, improving the visualisation of patchy inflammation and helping detect subtle dysplastic colonic lesions. Moreover, novel advanced tools, including probe-based confocal laser endomicroscopy and ultra-high magnification endocytoscopy, offer the remarkable ability to investigate the deep aspect of the gastrointestinal tract in real-time, including the structure and function of the intestinal barrier and inflammatory-related alterations. Thus, these techniques can bridge the gap between endoscopy and histology, enabling the integration of novel treat-to-target strategies associated with more favourable outcomes in clinical trials and clinical practice, including histological remission and barrier healing. Although still in its early stages, artificial intelligence represents a further step forward in overcoming the limitations associated with endoscopy, including subjectivity, high inter- and intra-observer variability and the requirement for expertise. AI holds promise in clinical trials to improve central read-out and facilitate patient screening and enrolment. |
|||
| Page Top | |||